AbbVie (NYSE:ABBV) Stock Gets Price Target Increase from Barclays

AbbVie (NYSE:ABBV – Get Free Report) had its price objective raised by stock analysts at Barclays from $325.00 to $335.00 in a research note issued on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 14.57% from the stock’s previous close.

Other research analysts have also recently issued reports about the company. Leerink Partners boosted their target price on AbbVie from $309.00 to $342.00 and gave the company an “outperform” rating in a research note on Monday, November 2nd. Wells Fargo & Company raised their price target on AbbVie from $300.00 to $340.00 and gave the stock an “overweight” rating in a research report on Monday, November 2nd. Piper Sandler raised their price target on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Royal Bank Of Canada lifted their price objective on AbbVie from $280.00 to $330.00 and gave the company an “outperform” rating in a report on Monday, November 2nd. Finally, Rothschild & Co Redburn boosted their price objective on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $297.85.

Get Our Latest Stock Analysis on AbbVie

AbbVie Trading Down 0.7%

AbbVie stock opened at $292.40 on Monday. The firm has a market capitalization of $516.85 billion, a P/E ratio of 50.33, a PEG ratio of 1.34 and a beta of 0.20. The business has a 50-day moving average of $277.14 and a 200-day moving average of $241.64. AbbVie has a 1 year low of $190.75 and a 1 year high of $302.93.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same period last year, the company posted $1.86 EPS. AbbVie’s revenue for the quarter was up 10.3% on a year-over-year basis. Research analysts anticipate that AbbVie will post 13.98 EPS for the current fiscal year.

Insider Buying and Selling

In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the sale, the executive vice president directly owned 83,171 shares of the company’s stock, valued at $24,419,005.60. The trade was a 32.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is owned by company insiders.

Institutional Trading of AbbVie

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Financial Freedom LLC purchased a new stake in shares of AbbVie in the 3rd quarter worth approximately $29,000. Burk Holdings LLC bought a new position in AbbVie during the 2nd quarter valued at approximately $30,000. Marquette Asset Management LLC increased its position in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after buying an additional 48 shares in the last quarter. IMG Wealth Management Inc. raised its stake in AbbVie by 3,060.0% during the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after buying an additional 153 shares during the last quarter. Finally, Principia Wealth Advisory LLC raised its stake in AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after buying an additional 44 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Recent AbbVie Headlines

Here are a few of the latest headlines about ABBV:

AbbVie Company Profile

(Get Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

See Also

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.